Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Isotretinoin embryopathy--a continuing problem.

E B Rappaport1, M Knapp

  • 1New Jersey Department of Health Special Child Health Services, Trenton 08625.

Journal of Clinical Pharmacology
|May 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utilizing pMHC Multimers to Study Antigen-Specific T Cells and T Cell Exhaustion in Chronic Viral Infections.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

Restaurants as Environments for Healthy Eating: Factors That Contribute to Restaurant-Based Healthy Eating Program Adoption.

Health promotion practice·2024
Same author

Endothelial lipase: regulation and biological function.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2022
Same author

MiRNA-149 as a Candidate for Facial Clefting and Neural Crest Cell Migration.

Journal of dental research·2021
Same author

'TB or not TB': the conundrum of pre-European contact tuberculosis in the Pacific.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2020
Same author

A systematic review and meta-analysis of dementia prevalence in seven developing countries: A STRiDE project.

Global public health·2020
Same journal

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

Journal of clinical pharmacology·2026
Same journal

New Insights into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban.

Journal of clinical pharmacology·2026
Same journal

Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population.

Journal of clinical pharmacology·2026
Same journal

The Journal of Clinical Pharmacology: 65 Years of History.

Journal of clinical pharmacology·2026
Same journal

Decoupling CAR-T Expansion, Conversion, and Decay Timing: Physiologically Aligned Semi-Mechanistic Modeling With Smooth Gating and a Cauchy Likelihood Residual Model.

Journal of clinical pharmacology·2026
Same journal

Mind the Gap: Unraveling the Pharmacokinetic Variability of Δ9-Tetrahydrocannabinol (THC).

Journal of clinical pharmacology·2026
See all related articles

First trimester exposure to isotretinoin causes a 20% risk of major birth defects. Despite warnings, isotretinoin embryopathy cases persist, necessitating evaluation of revised labeling for preventing fetal malformations.

Area of Science:

  • Teratology
  • Pharmacovigilance
  • Public Health

Background:

  • Isotretinoin use during the first trimester of pregnancy is linked to a significant risk of major fetal malformations.
  • Previous product labeling aimed to prevent inadvertent exposure but proved insufficient in preventing isotretinoin embryopathy.

Observation:

  • Five cases of isotretinoin embryopathy were identified in New Jersey following reports to the Birth Defects Registry.
  • These cases involved maternal use of isotretinoin during early pregnancy, leading to severe birth defects.

Findings:

  • The study describes five cases of isotretinoin embryopathy, detailing circumstances of first-trimester maternal exposure.
  • Despite contraindications and educational interventions, isotretinoin-related birth defects continued to occur.

Related Experiment Videos

Implications:

  • Manufacturer revised product labeling with enhanced warnings and patient consent sections following case reports and FDA investigations.
  • The effectiveness of these updated labeling changes in preventing future isotretinoin embryopathy requires rigorous evaluation.